OOIR: Observatory of International Research

Papers

(The TQCC of Melanoma Research is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients	41
Gut microbial species and metabolic pathways associated with response to treatment with immune checkpoint inhibitors in metastatic melanoma	41
Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM)	37
Estimated risk of progression of lentigo maligna to lentigo maligna melanoma	32
Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II)	27
Stage-specific incidence trends of melanoma in an English region, 1996–2015: longitudinal analyses of population-based data	23
Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature	23
Low-level laser irradiation potentiates anticancer activity of p-coumaric acid against human malignant melanoma cells	20
Ultraviolet radiation and cutaneous melanoma: a historical perspective	19
Clinical and molecular features of subungual melanomas are site-specific and distinct from acral melanomas	18
External validation of the American Joint Committee on Cancer 8th edition melanoma staging system: who needs adjuvant treatment?	17
Impact of COVID-19 on melanoma diagnosis	17
The molecular profile of mucosal melanoma	15
The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials	14
Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)	14
Staging 18F-FDG PET/CT influences the treatment plan in melanoma patients with satellite or in-transit metastases	13
A phase II study of the insulin-like growth factor type I receptor inhibitor IMC-A12 in patients with metastatic uveal melanoma	12
Severe blistering eruptions induced by immune checkpoint inhibitors: a multicentre international study of 32 cases	12
Hemophagocytic lymphohistiocytosis of a melanoma patient under BRAF/MEK-inhibitor therapy following anti-PD1 inhibitor treatment: a case report and review to the literature	10
Evolutionarily conserved resistance to phagocytosis observed in melanoma cells is insensitive to upregulation of pro-phagocytic signals and to CD47 blockade	10
C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting	10
Induced sarcoid-like reactions in patients with metastatic melanoma treated with dabrafenib and trametinib: a monocentric retrospective study	9
A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors	9
Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanoma	9
Concomitant development of neurologic and cardiac immune-related adverse effects in patients treated with immune checkpoint inhibitors for melanoma	9

Impact of staging on survival outcomes: a nationwide real-world cohort study of metastatic uveal melanoma	9
Impact of the development of immune related adverse events in metastatic melanoma treated with PD -1 inhibitors	9
Ultraviolet A radiation exposure and melanoma: a review	9
Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study	9
Metastatic acral melanoma treatment outcomes: a systematic review and meta-analysis	9
Vascular endothelial growth factor/semaphorin-3A ratio and SEMA3A expression in cutaneous malignant melanoma	9
Desmoplastic melanoma: an updated clinical review and the emerging role of genetic markers and immunotherapies	8
Ultra-high-frequency ultrasound monitoring of melanomas arising in congenital melanocytic nevi: a case series	8
Aseptic cystitis induced by nivolumab and ipilimumab combination for metastatic melanoma	8
Identification of prognostic mRNAs in metastatic cutaneous melanoma	7
Distinguishing melanophages from tumor in melanoma patients treated with talimogene laherparepvec	7
Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma	7
Prognostic impact of thyroid dysfunctions on progression-free survival in patients with metastatic melanoma treated with anti-PD-1 antibodies	7
Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target	7
Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors	7
Efficacy of radiotherapy combined with immune checkpoint inhibitors in patients with melanoma: a systemic review and meta-analysis	7
Utilization and impact of immunotherapy in stage IV melanoma using the National Cancer Database	7
A novel prognostic biomarker for cutaneous malignant melanoma: red cell distribution width (RDW) to lymphocyte ratio	6
Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases	6
Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma	6
Anti-PD-1 induced collagenous colitis in metastatic melanoma: a rare severe adverse event	6
ETS1 promoted cell growth, metastasis and epithelial–mesenchymal transition process in melanoma by regulating miR-16-mediated SOX4 expression	6
Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activ	6
The role of osteopontin in the development and metastasis of melanoma	6
Regression of nevi, vitiligo-like depigmentation and halo phenomenon may indicate response to immunotherapy and targeted therapy in melanoma	6
COVID-19 vaccination mimicking lymph-node progression in a patient with melanoma: a case report	6
Increased serum CCL26 level is a potential biomarker for the effectiveness of anti-PD1 antibodies in patients with advanced melanoma	6
Influence of IL1B (rs16944) and IL1R2 (rs4141134) polymorphisms on aggressiveness and prognosis of cutaneous melanoma	6
Utility of histone H3K27me3 and H4K20me as diagnostic indicators of melanoma	6
Melanogenesis and autophagy in melanoma	6
Time trends and age–period–cohort analysis of cutaneous malignant melanoma incidence rates in the Romagna Region (northern Italy), 1986–2014	6
Survival estimation of melanoma patients with brain metastasis using the Melanoma-molGPA score: external validation from a French cohort	5
Toxicity of combined targeted therapy and concurrent radiotherapy in metastatic melanoma patients: a single-center retrospective analysis	5
Intracellular signaling modules linking DNA damage to secretome changes in senescent melanoma cells	5
A meta-analysis of melanoma risk in industrial workers	5
Clinical outcomes and secondary glaucoma after gamma-knife radiosurgery and Ruthenium-106 brachytherapy for uveal melanoma: a single institution experience	5
Nonhomologous end-joining repair is likely involved in the repair of double-stranded DNA breaks induced by riluzole in melanoma cells	5
Recurrence risk of early-stage melanoma of the external ear: an investigation of surgical approach and sentinel lymph node status	5
Risk factors in pediatric melanoma: a retrospective study of 39 cases	5
A novel C-terminal Hsp90 inhibitor KU758 synergizes efficacy in combination with BRAF or MEK inhibitors and targets drug-resistant pathways in BRAF-mutant melanomas	5
An atypical sarcoid-like reaction during anti-protein death 1 treatment in a patient with metastatic melanoma	5
Very late recurrence of iris melanoma: 45 years after treatment	5
Genome-wide study on uveal melanoma patients finds association to DNA repair gene TDP1	5
MicroRNAs expression associated with aggressive clinicopathological features and poor prognosis in primary cutaneous melanomas	5
Diagnostic and prognostic value of heat shock protein 90α in malignant melanoma	5
GLI-1 polymorphisms of Hedgehog pathway as novel risk and prognostic biomarkers in melanoma patients	5
Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases	5
Combination of radiotherapy and targeted therapy for melanoma brain metastases: a systematic review	5
The successful use of pembrolizumab in a renal transplant recipient with metastatic melanoma	5
Vitamin D deficiency in melanoma patients is associated with worse overall survival: a retrospective cohort study	5

BRAF inhibitor treatment is feasible in the oldest-old advanced melanoma patients	4
Clinical performance indicators for monitoring the management of cutaneous melanoma: a population-based perspective	4
Exceptional response to combination ipilimumab and nivolumab in metastatic uveal melanoma: Insights from genomic analysis	4
PD-1 inhibitors might limit the development of brain metastases in patients with advanced melanoma	4
Seborrheic keratosis-like melanoma: a diagnostic challenge	4
Recombinant human Hsp110-gp100 chaperone complex vaccine is nontoxic and induces response in advanced stage melanoma patients	4
Tumor mutational burden and somatic mutation status to predict disease recurrence in advanced melanoma	4
Immune-related Bell’s palsy in melanoma patients treated with immune checkpoint inhibitors	4
Hemophagocytic lymphohistiocytosis in advanced melanoma treated with dabrafenib and trametinib combination: two cases	4
Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patients	4
PET-CT for staging pT4b melanomas prior to sentinel lymph node biopsy: a 5-year review	4
Real-world data on melanoma brain metastases and survival outcome	4
Phase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapy	4
Female melanoma and estrogen receptors expression: an immunohistochemical pilot study	4
Identification of heterogeneity and prognostic key genes associated with uveal melanoma using single-cell RNA-sequencing technology	4
Pembrolizumab-induced plaque psoriasis successfully treated with risankizumab in a patient with stage IV cutaneous melanoma	4
Silencing of CEBPB-AS1 modulates CEBPB expression and resensitizes BRAF-inhibitor resistant melanoma cells to vemurafenib	4
Proteomic profiles of melanoma cell-derived exosomes in plasma: discovery of potential biomarkers of melanoma progression	4
Melanotransferrin is efficiently sorted on the surface of exosomes secreted by melanoma cells	4
Antibody-drug conjugates: an evolving approach for melanoma treatment	4
Clinical and radiological evolution of cerebral amyloid angiopathy-related inflammation in the context of anti-PD-1 immunotherapy	4
Retrospective analysis of adjuvant therapy using dabrafenib plus trametinib in Japanese patients with advanced melanoma: analysis of 36 cases	4
Genomic profiling of a dedifferentiated mucosal melanoma following exposure to immunotherapy	4
Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma	4
MC1R variants and cutaneous melanoma risk according to histological type, body site, and Breslow thickness: a pooled analysis from the M-SKIP project	4
Epidemiology of cutaneous melanoma and melanoma in situ: a 10-year nationwide retrospective cohort study in South Korea	4
Expression of cathepsins B and D by cancer stem cells in head and neck metastatic malignant melanoma	4
Expression of the cancer stem cell marker OCT4 is associated with worse prognosis and survival in cutaneous melanoma	4
Case report: acute tumour lysis syndrome following encorafenib and binimetinib for v600E metastatic melanoma with large intra-abdominal mass	4
20-year assessment of metastatic latency and subsequent time to death after proton therapy for uveal melanomas	4
Induction of T helper 17 cell response by interleukin-7 in patients with primary cutaneous melanoma	4
Loss of skeletal muscle area and fat-free mass during dabrafenib/trametinib and vemurafenib/cobimetinib treatments in patients with BRAF-mutant metastatic malignant melanoma	4
Tissue microRNA expression profiling in hepatic and pulmonary metastatic melanoma	4
Clinical features, molecular characteristics and surgical management of primary penile mucosal melanoma based on the European Association of Urology Penile Cancer Guidelines	4
Patients with a history of atopy have fewer cutaneous melanomas than those without atopy: a cross-sectional study in 496 patients at risk of skin cancers	4
Complete response to talimogene laherparepvec in a primary acral lentiginous melanoma	4
LINC01063 functions as an oncogene in melanoma through regulation of miR-5194-mediated SOX12 expression	4